Sustained release of nanosized complexes of polyethylenimine and anti-TGF-beta 2 oligonucleotide improves the outcome of glaucoma surgery

Journal of Controlled Release : Official Journal of the Controlled Release Society
Ana L Gomes dos SantosElias Fattal

Abstract

The purpose of this study was to design microspheres combining sustained delivery and enhanced intracellular penetration for ocular administration of antisense oligonucleotides. Nanosized complexes of antisense TGF-beta2 phosphorothioate oligonucleotides (PS-ODN) with polyethylenimine (PEI), and naked PS-ODN were encapsulated into poly(lactide-co-glycolide) microspheres prepared by the double-emulsion solvent evaporation method. The PS-ODN was introduced either naked or complexed in the inner aqueous phase of the first emulsion. We observed a marked influence of microsphere composition on porosity, size distribution and PS-ODN encapsulation efficiency. Mainly, the presence of PEI induced the formation of large pores observed onto microsphere surface. Introduction of NaCl in the outer aqueous phase increased the encapsulation efficiency and reduced microsphere porosity. In vitro release kinetic of PS-ODN was also investigated. Clearly, the higher the porosity, the faster was the release and the higher was the burst effect. Using an analytical solution of Fick's second law of diffusion, it was shown that the early phase of PS-ODN and PS-ODN-PEI complex release was primarily controlled by pure diffusion, irrespectively of the type...Continue Reading

References

Oct 1, 1990·Current Eye Research·H D JampelA B Roberts
May 1, 1989·The Journal of Clinical Investigation·T B ConnorM Lansing
Feb 15, 1989·American Journal of Ophthalmology·A Sommer
Nov 1, 1971·Experimental Eye Research·A Bill, C I Phillips
Aug 1, 1995·Proceedings of the National Academy of Sciences of the United States of America·O BoussifJ P Behr
Oct 1, 1996·Journal of Glaucoma·H MietzG K Krieglstein
Jun 6, 2000·Advanced Drug Delivery Reviews·B DemeneixJ Remy
Aug 10, 2000·Nucleic Acids Research·N MignetJ C François
Feb 21, 2002·Journal of Controlled Release : Official Journal of the Controlled Release Society·K PaysF Leal-Calderon
Mar 29, 2002·Journal of Pharmaceutical Sciences·Giuseppe De RosaElias Fattal
May 4, 2002·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·N FaisantJ P Benoit
Dec 17, 2002·Journal of Cell Science·Justin P AnnesDaniel B Rifkin
Sep 18, 2004·Biochimica Et Biophysica Acta·Kenneth A HowardH Oya Alpar
Dec 30, 2004·Investigative Ophthalmology & Visual Science·Salvatore GrisantiKarl Ulrich Bartz-Schmidt

❮ Previous
Next ❯

Citations

Sep 2, 2008·Pharmaceutical Research·Ripal GaudanaAshim K Mitra
Jul 17, 2012·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Ramesh SrirangamSoumyajit Majumdar
Jun 2, 2011·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Raymond M SchiffelersGert Storm
Oct 5, 2011·Indian Journal of Pharmaceutical Sciences·R K KharF J Ahmad
Aug 25, 2007·Nanomedicine·Jo Vandervoort, Annick Ludwig
May 14, 2014·Progress in Retinal and Eye Research·Rocío Herrero-VanrellIrene Teresa Molina-Martínez
May 28, 2014·Journal of Controlled Release : Official Journal of the Controlled Release Society·Indu Pal Kaur, Shilpa Kakkar
Jun 6, 2008·Expert Opinion on Drug Delivery·S Dean Allison
Jun 26, 2009·Expert Opinion on Drug Delivery·Xiubo ZhaoJian R Lu
Apr 17, 2012·Drug Discovery Today·Gaurav K JainRoop K Khar
Feb 1, 2012·Journal of Controlled Release : Official Journal of the Controlled Release Society·Amélie Bochot, Elias Fattal
Oct 25, 2011·Journal of Controlled Release : Official Journal of the Controlled Release Society·Juergen Siepmann, Florence Siepmann
Dec 21, 2010·Drug Discovery Today·Thilini Rasika ThrimawithanaRaid Ghassan Alany
Mar 11, 2009·Advanced Drug Delivery Reviews·Yogita Krishnamachari, Aliasger K Salem
Apr 1, 2008·Journal of Controlled Release : Official Journal of the Controlled Release Society·Carolina Gómez-GaeteNicolas Tsapis
Oct 6, 2015·Journal of Controlled Release : Official Journal of the Controlled Release Society·Vianney DelplaceMolly Shoichet
Mar 19, 2014·The Journal of Pharmacy and Pharmacology·Sahil P Chaplot, Ilva D Rupenthal
Nov 23, 2006·Journal of Controlled Release : Official Journal of the Controlled Release Society·Hervé HillaireauPatrick Couvreur
Nov 14, 2006·Advanced Drug Delivery Reviews·Arto Urtti
Nov 14, 2006·Advanced Drug Delivery Reviews·Elias Fattal, Amélie Bochot
Nov 11, 2006·Advanced Drug Delivery Reviews·C BloquelF Behar-Cohen
Sep 10, 2015·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Joanne E Murphy-Ullrich, J Crawford Downs
Nov 13, 2012·Current Opinion in Pharmacology·Marco Attilio ZarbinRobert Ritch
Jul 16, 2008·International Journal of Pharmaceutics·Elias Fattal, Amélie Bochot
Sep 18, 2007·Current Opinion in Allergy and Clinical Immunology·Stephen C Pflugfelder, Michael E Stern
Feb 16, 2008·Drug Discovery Today·Eva M Del Amo, Arto Urtti
Oct 22, 2016·Drug Delivery and Translational Research·I Bravo-OsunaR Herrero-Vanrell
May 17, 2019·Expert Opinion on Drug Delivery·Francine Behar-Cohen
Oct 17, 2013·The Journal of Pharmacy and Pharmacology·Raghu Raj Singh ThakurDavid S Jones
Dec 12, 2019·Advances in Therapy·Marcelo Luís OcchiuttoAnastasios G Konstas
Jul 28, 2020·Acta Ophthalmologica·Rachel S ChongTina T Wong
Mar 27, 2021·International Journal of Pharmaceutics·Romain CanioniNicolas Tsapis
May 26, 2021·Advanced Drug Delivery Reviews·Elias Fattal, François Fay

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.